… .” Operational Highlights for Q2 2025 Progress with marketed … fully recognized as revenue in the second quarter of 2025 Post … . This change in profitability reflects the combined effect … –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma …

Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 …

Q2: 2025-08-07 Earnings Summary … .10 beats by $0.07  | Revenue of $68.13M (64.15% … by Avadel Pharmaceuticals plc in conjunction with their 2025 Q2 earnings call …

… pharmaceutical company focused on therapies for cancer, released its second quarter … revenue. This period marked a return to profitability … Metric Q2 2025 Q2 2025 Estimate Q2 2024 … could cause revenue variability quarter to quarter. Royalty revenue, reflecting …

Annual Recurring Revenue (ARR)(1) up 55% YoY to $79.6 million Total Revenue up 47% YoY to $23.9 million Adjusted EBITDA(1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “ …

Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival …

… highlights. “In the second quarter, we made strong progress … highlighted a favorable pharmacokinetic and tolerability profile … Chief Financial Officer. Second Quarter 2025 Financial Highlights Cash … from existing collaborations. Revenue Revenue was $63.7 …

AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase …

Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) --  AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent …

SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. …